Ellsworth Advisors’s Pacira BioSciences PCRX Stock Holding History

Ellsworth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.11M	Buy	+44,284	New	+$1.12M	0.18%	101

Other funds holding PCRX

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

ATC

Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Ellsworth Advisors's PCRX Position: Q3 2026 in Review

Ellsworth Advisors opened a new position in Pacira BioSciences (PCRX) in Q3 2026: 44,284 shares worth $1.11M. The stake represents 0.18% of the portfolio and ranks #101 among its holdings.

17 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

Ellsworth Advisors held 44,284 shares of Pacira BioSciences worth $1.11M as of Q3 2026.
Pacira BioSciences was a new Ellsworth Advisors position in Q3 2026.
Pacira BioSciences made up 0.18% of Ellsworth Advisors's portfolio in Q3 2026, its #101 holding.
17 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.